Patient Reported Outcomes Conference Key Takeaways

May 9, 2012
Lisa Henderson

Lisa Henderson is Editor-in-Chief of Applied Clinical Trials and Pharm Exec. She can be reached at lhenderson@mmhgroup.com.

Applied Clinical Trials

On Monday and Tuesday of this week, CBI's 9th Forum on Patient Reported Outcomes was held in Philadelphia. The expert presenters from pharma, CROs, service providers and academic health centers covered a variety of topics on how to ensure the validity of PRO concepts, patient data and new technologies.

The co-chairs of the event, Ari Gnanasakthy, Executive Director, HE&OR, Novartis, and Susan Vallow, Director for Patient Reported Outcomes at Janssen Global Services, LLC, noted the following emerging themes from the conference as important to the PRO audience in the upcoming months: FDA/EMA regulations; increasing use of PRO in the post-registration environment; how best to use PRO as a quality measure; mixed modality usage and how new collaborative initiatives across the industry are being used to combat inefficiencies in development and how they impact PROs.

Related Content:

News